Tags

Type your tag names separated by a space and hit enter

Mesenchymal stem cell therapy for severe COVID-19.
Signal Transduct Target Ther. 2021 09 08; 6(1):339.ST

Abstract

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a global public burden on health authorities. Although the virological characteristics and pathogenesis of COVID-19 has been largely clarified, there is currently no specific therapeutic measure. In severe cases, acute SARS-CoV-2 infection leads to immune disorders and damage to both the adaptive and innate immune responses. Having roles in immune regulation and regeneration, mesenchymal stem cells (MSCs) serving as a therapeutic option may regulate the over-activated inflammatory response and promote recovery of lung damage. Since the outbreak of the COVID-19 pandemic, a series of MSC-therapy clinical trials has been conducted. The findings indicate that MSC treatment not only significantly reduces lung damage, but also improves patient recovery with safety and good immune tolerance. Herein, we summarize the recent progress in MSC therapy for COVID-19 and highlight the challenges in the field.

Authors+Show Affiliations

Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China.Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China.Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China.Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China.Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China.Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China.Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China.Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China.Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China.Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China. fswang302@163.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

34497264

Citation

Shi, Lei, et al. "Mesenchymal Stem Cell Therapy for Severe COVID-19." Signal Transduction and Targeted Therapy, vol. 6, no. 1, 2021, p. 339.
Shi L, Wang L, Xu R, et al. Mesenchymal stem cell therapy for severe COVID-19. Signal Transduct Target Ther. 2021;6(1):339.
Shi, L., Wang, L., Xu, R., Zhang, C., Xie, Y., Liu, K., Li, T., Hu, W., Zhen, C., & Wang, F. S. (2021). Mesenchymal stem cell therapy for severe COVID-19. Signal Transduction and Targeted Therapy, 6(1), 339. https://doi.org/10.1038/s41392-021-00754-6
Shi L, et al. Mesenchymal Stem Cell Therapy for Severe COVID-19. Signal Transduct Target Ther. 2021 09 8;6(1):339. PubMed PMID: 34497264.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mesenchymal stem cell therapy for severe COVID-19. AU - Shi,Lei, AU - Wang,Lifeng, AU - Xu,Ruonan, AU - Zhang,Chao, AU - Xie,Yunbo, AU - Liu,Kai, AU - Li,Tiantian, AU - Hu,Wei, AU - Zhen,Cheng, AU - Wang,Fu-Sheng, Y1 - 2021/09/08/ PY - 2021/04/01/received PY - 2021/08/24/accepted PY - 2021/07/27/revised PY - 2021/9/9/entrez PY - 2021/9/10/pubmed PY - 2021/9/21/medline SP - 339 EP - 339 JF - Signal transduction and targeted therapy JO - Signal Transduct Target Ther VL - 6 IS - 1 N2 - The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a global public burden on health authorities. Although the virological characteristics and pathogenesis of COVID-19 has been largely clarified, there is currently no specific therapeutic measure. In severe cases, acute SARS-CoV-2 infection leads to immune disorders and damage to both the adaptive and innate immune responses. Having roles in immune regulation and regeneration, mesenchymal stem cells (MSCs) serving as a therapeutic option may regulate the over-activated inflammatory response and promote recovery of lung damage. Since the outbreak of the COVID-19 pandemic, a series of MSC-therapy clinical trials has been conducted. The findings indicate that MSC treatment not only significantly reduces lung damage, but also improves patient recovery with safety and good immune tolerance. Herein, we summarize the recent progress in MSC therapy for COVID-19 and highlight the challenges in the field. SN - 2059-3635 UR - https://www.unboundmedicine.com/medline/citation/34497264/Mesenchymal_stem_cell_therapy_for_severe_COVID_19_ L2 - https://doi.org/10.1038/s41392-021-00754-6 DB - PRIME DP - Unbound Medicine ER -